Observational Study of Pediatric Inpatient Pain, Nausea/Vomiting and Anxiety

Michael Schlegelmilch1, Salima Punja2, Hsing Jou3,4

  • 1University of Alberta, Faculty of Medicine and Dentistry, Edmonton, AB , T6G 2R3, Canada. mschlege@ualberta.ca.

Insights

Anxiety is the most common and severe symptom in hospitalized children. While pain and nausea severity varied by service, anxiety levels were similar across pediatric units.

Area of Science:

  • Pediatric hospital medicine
  • Childhood symptomology
  • Clinical research

Background:

  • The prevalence and severity of pain, nausea/vomiting, and anxiety (PNVA) in hospitalized children are not well-established.
  • This study investigates PNVA in pediatric patients across oncology, general pediatrics, and cardiology services at a tertiary care center.

Purpose of the Study:

  • To determine the prevalence and severity of PNVA in hospitalized children.
  • To compare PNVA symptoms and their co-occurrence across different pediatric clinical services.

Main Methods:

  • A prospective study enrolled 496 hospitalized children whose caregivers consented.
  • Symptoms of pain, nausea/vomiting, and anxiety were measured on weekdays using age-validated tools.
  • Data were analyzed to compare prevalence and severity across oncology, general pediatrics, and cardiology services.

Main Results:

  • Anxiety was the most frequently reported symptom (65.6%), followed by nausea (55.4%) and pain (52.0%).
  • Mean severity scores were highest for anxiety (3.7/10), followed by nausea (3.2/10) and pain (3.0/10).
  • While PNVA prevalence did not differ by service, pain and nausea severity were significantly lower in the oncology service.

Conclusions:

  • Anxiety is the most prevalent and severe symptom experienced by hospitalized children.
  • Oncology patients reported less severe pain and nausea compared to other services, with no significant difference in anxiety levels.
  • PNVA symptoms frequently co-occurred, highlighting the need for comprehensive symptom management in pediatric hospital care.

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
719
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
627
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
836
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
610
Observational Studies01:11

Observational Studies

Observational studies are a type of analytical study where researchers observe events without any interventions. In other words, the researcher does not influence the response variable or the experiment's outcome.
There are three types of observational studies – Prospective, retrospective, and cross-sectional.
Prospective Study
Prospective studies, also known as longitudinal or cohort studies, are carried out by collecting future data from groups sharing similar characteristics. One...
10.8K
Pathophysiology of Vomiting01:22

Pathophysiology of Vomiting

Vomiting is a complex physiological response to expel harmful or irritating substances from the body. It's a defensive mechanism triggered by stimuli like poisons, microbial toxins, cytotoxic drugs, and mechanical abdominal distension. The process is centrally coordinated by the vomiting (or emetic) center located in the medulla of the brainstem. This area, rich in muscarinic M1, histamine H1, neurokinin 1 (NK1), and serotonin 5-HT3 receptors, coordinates the act of vomiting through...
2.9K